2021 Monoclonal Antibody & Recombinant Protein Market Report & CDMO Pricing Study

2021 Monoclonal Antibody & Recombinant Protein Market Report & CDMO Pricing Study

Order now and learn more about:

  • Comprehensive landscape of top 85 Biopharmaceutical CDMOs
  • Current 2021 pricing benchmarks, difficult to find
  • Detailed pricing from your competitors across NA, EU, and Asia
  • Industry KOL feedback on the current market trends
  • 205 pages of primary research for your sales team

2021 Monoclonal Antibody & Recombinant Protein Market Report & CDMO Pricing Study Brings Value to Innovators, CDMOs, & PE Investors

Invaluable Peer Comparison for CDMOs or PE Investors –– Updated for 2021

If you are a CDMO serving the biologics outsourcing market, or a PE company or investor looking to define your investing strategy, you need our 2021 Monoclonal Antibody & Recombinant Protein Market Report & CDMO Pricing Study to bolster your understanding of your competitive arena, assess how you measure up on pricing, and position your company effectively to get on shortlists. The 2021 Monoclonal Antibody & Recombinant Protein Market Report & CDMO Pricing Study extends Nice Insight’s 2019 CDMO Biologics Report with updated, current pricing data and assessments of how the market has shifted over the last two years. Access current pricing data that is typically impossible to come by.

Exceptional Source of Due Diligence & Pricing for Innovators –– Updated for 2021

If you are an innovator – large or small/virtual – looking to outsource your biologics development and manufacturing, our 2021 Monoclonal Antibody & Recombinant Protein Market Report & CDMO Pricing Study is a rich resource for introduction and information on 85 Biologics CDMOs that might be ideal for you. Whether you purchased the 2019 report or not, the current, 2021 pricing data will help you understand what you should pay with competitive pricing comparisons.

What You Get With the Report

  • Current 2021 pricing benchmarks based on actual quotes given by providers for all typical service line items within biologic development projects.
  • Ability to measure whether your pricing levels are right against high, low, and median pricing in the marketplace.
  • A comprehensive view of the competitive landscape with a directory of the Top 85 Biopharmaceutical CDMOs across major regions today, including capabilities, capacity, proprietary technologies, and locations.
  • Input from subject matter experts (SMEs) from CDMOs and buyers of outsourced services.
  • Projections on ongoing growth of the biologics market, including segmentation such as biosimilars, orphan drugs, growth factors, etc.
  • Segmented breakdown of the biologics development market by scientific process, therapeutic areas, regions, clinical and commercial production, etc.
  • Analysis of advanced therapeutics in development, novel expression platforms, and advances in technology.

Gain More Understanding Of:

  • High, low, and median pricing for all typical Biologics CDMO services
  • Benchmark pricing and capacities among 85 CDMOs in biologics
  • The leading Biologics CDMO providers globally, region to region
  • Where capacity exists worldwide
  • Awareness levels and perceptions of Biologics CDMO providers
  • What matters to buyers of outsourced services / innovators seeking a CDMO
  • Methodologies / processes used to select CDMOs, including consultants

Monoclonal Antibody and Recombinant Protein CDMO Pricing Study

Pricing benchmarks cover line items under:

  • Methodology
  • Discovery / Cell Line Development / IND
  • Analytical Work
  • Engineering / Manufacturing Run
  • Additional Analytical Development
  • Commercial Manufacturing

Monoclonal Antibody and Recombinant Protein Market Report

  • Introduction and Background
    • Biopharmaceutical Manufacturing
    • Establishment of the Biologics CDMO Sector
    • Maturing and Preliminary Shakedown of the Biologics CDMO Sector
    • Capacity, Capacity, Capacity
    • Continuing Investment
    • Supply Chain and Talent Barriers Remain Areas of Concern
    • Looking to the Future
  • Section I: Biopharma Market Overview
    • Study Methodology
    • Key Market Drivers
    • Market Size - Projections About Overall Global Biopharma Market
    • Market by Therapeutic Area
  • Section II: Biopharmaceutical Production and Technologies
    • Expression Systems
    • Mammalian Expression Systems
    • Microbial Expression Systems
    • Other - Plant and Insect Based Systems
    • Plant-Based Expression
    • Insect Cell-Based Expression
    • Potentially Disruptive Expression and Production Technologies
    • Expression in System Market Size
    • Advances in Biopharmaceutical Processing
    • Technologies and Advances in Upstream Processing
    • Technologies and Advances in Downstream Processing
    • Technologies and Advances in Analytical Techniques
    • The Promise of Continuous Manufacturing
    • Electronic Systems and Digital Advances
  • Section III: Biopharma Market by Product Type:
    • Recombinant Proteins Including Antibodies and ADCs
    • Monoclonal Antibodies
    • Antibody–Drug Conjugates
    • Plasmid Proteins - Key Products and Technologies
    • Hormones
    • Growth Factors
    • Vaccines
    • Global Market
    • Recombinant Vaccines
    • Biosimilars
    • Next-Generation Therapies
    • Next-Generation Antibody Products
    • Viral Vector Products
    • Gene and Gene-Modified Therapies
    • Cell Therapies
  • Section IV: Biopharma Market by Development Stage
  • Section V: Biopharma Contract Development and Manufacturing Market
    • Market Definition
    • Overall Market Size and State
    • Services Offered by Biopharmaceutical CDMOs
    • Cell Line and Strain Development and Selection
    • Cell Banking and Characterization
    • Process Development, Optimization, Scale-up, and Technology Transfer
    • cGMP Drug Substance Manufacture
    • Biopharmaceutical CDMO Market Size and Growth
    • Biopharmaceutical CDMO Market Fragmentation & Consolidation
  • Section VI: Capacity Expansion and Investment
  • Section VII: Barriers to Entry and Hurdles to Growth
    • Global Talent Shortage
    • Supply Chain Concerns
  • Section VIII: Regional Analysis
  • Section IX: Biopharma Outsourced Manufacturing Pricing Study
    • Study Methodology
    • Pricing Matrix
  • Appendix I: Supplier Profiles
  • Appendix II: References